반응형

HFE 7

[Emergo, UL] What is a cognitive walkthrough, and why are they beneficial to medical device development?

Addressing potential usability issues early in the human factors engineering (HFE) process can save your team time and money over the course of development while providing evidence of a robust human factors process to regulatory agencies. Cognitive walkthroughs are a powerful method to identify potential usability issues in early development stages when initial decisions about design directions ..

뉴스 보고서 2025.04.04

[Emergo, UL] Webinar: Insights and expertise gained from a year of applying the 2024 HF guidance

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Determining when to utilize the pre-submissions Q-submission (Pre-Sub) Process▶ 일시: 2025년 03월 12일 CST 9시 (한국시간: 03월 12일 23시)  China’s medical product regulator, the National Medical Product Administration (NMPA), finalized their Human Factors (HF) guidance “Guidelines for the review of medical device usability engineering registration” in March 2024. The guidance..

뉴스 보고서 2025.02.25

[Emergo, UL] How to Conduct a Known Problems Analysis (KPA) for NMPA Compliance

Why a known problems analysis is crucial for NMPA complianceA known problems analysis (KPA) is a human factors engineering (HFE) activity that aims to identify use issues and user interface flaws with devices currently on the market. Regulators require medical device manufacturers to conduct a KPA to investigate use problems associated with devices that are similar to a device under development ..

뉴스 보고서 2025.02.06

[Emergo, UL] What Does it Mean for a Device to be Inherently Safe by Design?

Both the FDA’s Human Factors Engineering (HFE) guidance and the global HFE standard IEC-62366 list “inherent safety by design” as the most effective method of managing use-related risks associated with medical devices. In this article, we discuss what is meant by safety by design, provide examples of products that demonstrate it and explore how it can be implemented within medical device design...

뉴스 보고서 2024.12.18

[Emergo, UL] New FDA Guidance: Use-Related Risk Analyses for Drugs, Biological Products and Combination Products

The U.S. Food and Drug Administration (FDA) issued a new draft human factors engineering (HFE) guidance document, Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products, on July 8, 2024. The guidance informs manufacturers of drug- and biologic-led combination products about the purpose and content of a use-related risk analysis (URRA) and how a ..

뉴스 보고서 2024.08.09

[Emergo, UL] Webinar: Best Practices for Engaging with the US FDA on Human Factors Strategy

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Best Practices for Engaging with the US FDA on Human Factors Strategy▶ 일시: 2024년 07월 11일 EST 10시 (한국시간: 07월 11일 23시)  Engaging with the U.S. Food and Drug Administration (FDA) on your human factors engineering (HFE) strategy is an important step toward achieving a successful medical product submission and subsequent U.S. market access. In this webinar, the presen..

반응형